Combination Immunotherapy Targeting Melanoma

Sponsor
Shenzhen Geno-Immune Medical Institute
Study ID
NCT06739226
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Antigen-specific CAR T, CTL and DCvac to treat melanoma. — BIOLOGICAL
    Antigen-specific CAR T, CTL and DCvac to treat melanoma.

Study Details

The purpose of this study is to assess the feasibility, safety and efficacy of combination immunotherapy based on CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines modified with GM-CSF and B7-2 (CD86) against melanoma, which targets CAR T specific surface antigens such as GD2, CTL specific antigens such as MAGE-A4, gp100 and a pool of melanoma specific antigens presented by the DCs. Another goal of the study is to learn more about the function and persistence of the CAR T cells and antigen-specific immune effectors in patients.

Key Dates

First listed
Dec 18, 2024
Start date
Aug 31, 2025
Status verified
Sep 2025
Primary completion
Dec 31, 2028
Completion
Dec 31, 2029

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CAR T/CTL/DCvac cells to treat melanoma
    Antigen-specific CAR T, CTL and DCvac to treat melanoma.

Primary Outcome Measure

Number of patients with adverse events [ Time Frame: 1 year ]

Central Contacts

Find similar trials

Nationwide
Melanoma trialsOncology trialsSkin cancer trialsDermatology trials

Related Studies